Cargando…

Pharmacological Small Molecules against Prostate Cancer by Enhancing Function of Death Receptor 5

Death receptor 5 (DR5) is a membrane protein that mediates exogenous apoptosis. Based on its function, it is considered to be a target for the treatment of cancers including prostate cancer. It is encouraging to note that a number of drugs targeting DR5 are now progressing to different stages of cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Gan, Xia, Liu, Yonghong, Wang, Xueni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413322/
https://www.ncbi.nlm.nih.gov/pubmed/36015177
http://dx.doi.org/10.3390/ph15081029
_version_ 1784775714154741760
author Gan, Xia
Liu, Yonghong
Wang, Xueni
author_facet Gan, Xia
Liu, Yonghong
Wang, Xueni
author_sort Gan, Xia
collection PubMed
description Death receptor 5 (DR5) is a membrane protein that mediates exogenous apoptosis. Based on its function, it is considered to be a target for the treatment of cancers including prostate cancer. It is encouraging to note that a number of drugs targeting DR5 are now progressing to different stages of clinical trial studies. We collected 38 active compounds that could produce anti-prostate-cancer effects by modulating DR5, 28 of which were natural compounds and 10 of which were synthetic compounds. In addition, 6 clinically used chemotherapeutic agents have also been shown to promote DR5 expression and thus exert apoptosis-inducing effects in prostate cancer cells. These compounds promote the expression of DR5, thereby enhancing its function in inducing apoptosis. When these compounds were used in combination with the natural ligand of DR5, the number of apoptotic cells was significantly increased. These compounds are all promising for development as anti-prostate-cancer drugs, while most of these compounds are currently being evaluated for their anti-prostate-cancer effects at the cellular level and in animal studies. A great deal of more in-depth research is needed to evaluate whether they can be developed as drugs. We collected literature reports on small molecules against prostate cancer through modulation of DR5 to understand the current dynamics in this field and to evaluate the prospects of small molecules against prostate cancer through modulation of DR5.
format Online
Article
Text
id pubmed-9413322
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94133222022-08-27 Pharmacological Small Molecules against Prostate Cancer by Enhancing Function of Death Receptor 5 Gan, Xia Liu, Yonghong Wang, Xueni Pharmaceuticals (Basel) Review Death receptor 5 (DR5) is a membrane protein that mediates exogenous apoptosis. Based on its function, it is considered to be a target for the treatment of cancers including prostate cancer. It is encouraging to note that a number of drugs targeting DR5 are now progressing to different stages of clinical trial studies. We collected 38 active compounds that could produce anti-prostate-cancer effects by modulating DR5, 28 of which were natural compounds and 10 of which were synthetic compounds. In addition, 6 clinically used chemotherapeutic agents have also been shown to promote DR5 expression and thus exert apoptosis-inducing effects in prostate cancer cells. These compounds promote the expression of DR5, thereby enhancing its function in inducing apoptosis. When these compounds were used in combination with the natural ligand of DR5, the number of apoptotic cells was significantly increased. These compounds are all promising for development as anti-prostate-cancer drugs, while most of these compounds are currently being evaluated for their anti-prostate-cancer effects at the cellular level and in animal studies. A great deal of more in-depth research is needed to evaluate whether they can be developed as drugs. We collected literature reports on small molecules against prostate cancer through modulation of DR5 to understand the current dynamics in this field and to evaluate the prospects of small molecules against prostate cancer through modulation of DR5. MDPI 2022-08-21 /pmc/articles/PMC9413322/ /pubmed/36015177 http://dx.doi.org/10.3390/ph15081029 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Gan, Xia
Liu, Yonghong
Wang, Xueni
Pharmacological Small Molecules against Prostate Cancer by Enhancing Function of Death Receptor 5
title Pharmacological Small Molecules against Prostate Cancer by Enhancing Function of Death Receptor 5
title_full Pharmacological Small Molecules against Prostate Cancer by Enhancing Function of Death Receptor 5
title_fullStr Pharmacological Small Molecules against Prostate Cancer by Enhancing Function of Death Receptor 5
title_full_unstemmed Pharmacological Small Molecules against Prostate Cancer by Enhancing Function of Death Receptor 5
title_short Pharmacological Small Molecules against Prostate Cancer by Enhancing Function of Death Receptor 5
title_sort pharmacological small molecules against prostate cancer by enhancing function of death receptor 5
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413322/
https://www.ncbi.nlm.nih.gov/pubmed/36015177
http://dx.doi.org/10.3390/ph15081029
work_keys_str_mv AT ganxia pharmacologicalsmallmoleculesagainstprostatecancerbyenhancingfunctionofdeathreceptor5
AT liuyonghong pharmacologicalsmallmoleculesagainstprostatecancerbyenhancingfunctionofdeathreceptor5
AT wangxueni pharmacologicalsmallmoleculesagainstprostatecancerbyenhancingfunctionofdeathreceptor5